These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35626120)

  • 1. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.
    Rentsch V; Seipel K; Banz Y; Wiedemann G; Porret N; Bacher U; Pabst T
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glofitamab: First Approval.
    Shirley M
    Drugs; 2023 Jul; 83(10):935-941. PubMed ID: 37285013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Dickinson MJ; Carlo-Stella C; Morschhauser F; Bachy E; Corradini P; Iacoboni G; Khan C; Wróbel T; Offner F; Trněný M; Wu SJ; Cartron G; Hertzberg M; Sureda A; Perez-Callejo D; Lundberg L; Relf J; Dixon M; Clark E; Humphrey K; Hutchings M
    N Engl J Med; 2022 Dec; 387(24):2220-2231. PubMed ID: 36507690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
    Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
    J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
    Polgarova K; Trneny M
    Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
    Trabolsi A; Arumov A; Schatz JH
    Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance of radiotherapy with concomitant glofitamab in diffuse large B cell lymphoma: a case report.
    Loap P; Johnson N; Birsen R; Decroocq J; Kirova Y
    Strahlenther Onkol; 2024 Jul; ():. PubMed ID: 38955824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOHO State of the Art Updates and Next Questions | Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma.
    Bennett R; Dickinson M
    Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38871556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.
    Birtas Atesoglu E; Gulbas Z; Uzay A; Ozcan M; Ozkalemkas F; Dal MS; Kalyon H; Akay OM; Deveci B; Bekoz H; Sevindik OG; Toptas T; Yilmaz F; Koyun D; Alkis N; Alacacioglu I; Sonmez M; Yavasoglu I; Tombak A; Mehtap O; Kurnaz F; Yuce OK; Karakus V; Turgut M; Kurekci DD; Ayer M; Keklik M; Buyuktas D; Ozbalak M; Ferhanoglu B
    Hematol Oncol; 2023 Oct; 41(4):663-673. PubMed ID: 37211991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.
    Ping N; Qu C; Li M; Kang L; Kong D; Chen X; Wu Q; Xia F; Yu L; Yao H; Yan L; Wu D; Jin Z
    Ann Transl Med; 2022 Mar; 10(6):298. PubMed ID: 35433994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.
    Zhu H; Deng H; Mu J; Lyu C; Jiang Y; Deng Q
    Onco Targets Ther; 2021; 14():4023-4037. PubMed ID: 34239307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.
    Huang C; Wu L; Liu R; Li W; Li Z; Li J; Liu L; Shan B
    Ann Transl Med; 2020 Sep; 8(17):1048. PubMed ID: 33145267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 17. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
    Zhou L; Zhao H; Shao Y; Chen X; Hong R; Wang L; Ni F; Nagler A; Hu Y; Huang H
    J Cancer; 2021; 12(18):5423-5431. PubMed ID: 34405005
    [No Abstract]   [Full Text] [Related]  

  • 18. Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan.
    Hsu YT; Wu SJ; Kao HW; Hsiao SY; Liao CK; Chen TY; Wang MC
    Cancer; 2024 Jun; 130(11):1972-1981. PubMed ID: 38306242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
    Broder MS; Ma Q; Yan T; Zhang J; Chang E; Kuzan D; Eldjerou L
    Am Health Drug Benefits; 2020; 13(5):192-199. PubMed ID: 33343819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.